Our study revealed that the group with high CDKN2A expression had a much greater TIDE, Dysfunction, and CD8 scores than the group with low CDKN2A expression, implying that immunotherapy is more effective in treating colorectal cancers with high CDKN2A expression (Fig. 10). This evidence concerns the gene CDKN2A and colorectal cancer.